0001209191-21-003168.txt : 20210111 0001209191-21-003168.hdr.sgml : 20210111 20210111211816 ACCESSION NUMBER: 0001209191-21-003168 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210107 FILED AS OF DATE: 20210111 DATE AS OF CHANGE: 20210111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aurentz Vincent CENTRAL INDEX KEY: 0001657494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 21522235 BUSINESS ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 453-7200 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Vincent Aurentz DATE OF NAME CHANGE: 20151103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-07 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001657494 Aurentz Vincent C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 Executive VP and CBO Common Stock 2021-01-07 4 M 0 18000 0.00 A 27000 D Performance Restricted Stock Unit 2021-01-07 4 M 0 18000 0.00 D 2022-01-03 Common Stock 18000 0 D On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 6,300 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 6,300 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 12,600 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein. The amount reported in Column 7 of Table II represents the common shares that vested on January 7, 2021. The PRSUs have now fully vested and no common shares remain issuable thereunder. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2021-01-11